Tags

Type your tag names separated by a space and hit enter

Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.
Ann N Y Acad Sci 2010; 1194:199-206AN

Abstract

Neurotrophic corneal defects are difficult to heal and all too often lead to scarring and vision loss. Medical management is often of limited success. We describe the results of nine patients (ages 37-84) with chronic nonhealing neurotrophic corneal epithelial defects who were treated with thymosin beta 4 (Tbeta4) sterile eye drops for 28 or 49 days with a follow-up period of 30 days. Those with geographic defects (six patients) showed dramatic healing without clinically significant neovascularization. Stromal thinning was observed in one patient. Three patients with punctate epithelial defects did not have a demonstrable change in their clinical findings. Reduced ocular irritation was reported by all patients soon after treatment initiation. Results from these compassionate use cases indicate that Tbeta4 may provide a novel, topical approach to wound healing in chronic nonhealing neurotrophic corneal ulcers.

Authors+Show Affiliations

Department of Ophthalmology, Children's Hospital of Michigan, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA. stevenpdunn@ameritech.net

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20536469

Citation

Dunn, Steven P., et al. "Treatment of Chronic Nonhealing Neurotrophic Corneal Epithelial Defects With Thymosin Beta4." Annals of the New York Academy of Sciences, vol. 1194, 2010, pp. 199-206.
Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010;1194:199-206.
Dunn, S. P., Heidemann, D. G., Chow, C. Y., Crockford, D., Turjman, N., Angel, J., ... Sosne, G. (2010). Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Annals of the New York Academy of Sciences, 1194, pp. 199-206. doi:10.1111/j.1749-6632.2010.05471.x.
Dunn SP, et al. Treatment of Chronic Nonhealing Neurotrophic Corneal Epithelial Defects With Thymosin Beta4. Ann N Y Acad Sci. 2010;1194:199-206. PubMed PMID: 20536469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. AU - Dunn,Steven P, AU - Heidemann,David G, AU - Chow,Christopher Y C, AU - Crockford,David, AU - Turjman,Nabila, AU - Angel,Janet, AU - Allan,Christian B, AU - Sosne,Gabriel, PY - 2010/6/12/entrez PY - 2010/6/12/pubmed PY - 2010/7/2/medline SP - 199 EP - 206 JF - Annals of the New York Academy of Sciences JO - Ann. N. Y. Acad. Sci. VL - 1194 N2 - Neurotrophic corneal defects are difficult to heal and all too often lead to scarring and vision loss. Medical management is often of limited success. We describe the results of nine patients (ages 37-84) with chronic nonhealing neurotrophic corneal epithelial defects who were treated with thymosin beta 4 (Tbeta4) sterile eye drops for 28 or 49 days with a follow-up period of 30 days. Those with geographic defects (six patients) showed dramatic healing without clinically significant neovascularization. Stromal thinning was observed in one patient. Three patients with punctate epithelial defects did not have a demonstrable change in their clinical findings. Reduced ocular irritation was reported by all patients soon after treatment initiation. Results from these compassionate use cases indicate that Tbeta4 may provide a novel, topical approach to wound healing in chronic nonhealing neurotrophic corneal ulcers. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/20536469/Treatment_of_chronic_nonhealing_neurotrophic_corneal_epithelial_defects_with_thymosin_beta4 L2 - https://doi.org/10.1111/j.1749-6632.2010.05471.x DB - PRIME DP - Unbound Medicine ER -